Glyburide (generic), Micronase, Diabeta Newswire

Glyburide (generic), Micronase, Diabeta Newswire

Comprehensive Real-Time News Feed for Glyburide (generic), Micronase, Diabeta.

Results 1 - 20 of 73 in Glyburide (generic), Micronase, Diabeta

  1. chlorpropamide, DiabineseRead the original story w/Photo

    Monday Aug 7 | MedicineNet

    Chlorpropamide is an oral blood sugar -lowering drug in a class of medications for diabetes treatment called sulfonylureas. It is one of the first four sulfonylureas to be used to manage type II diabetes and it is commonly referred to as a first generation sulfonylurea.

    Comment?

  2. W.Va. AG Alleges Drug Manufacturers Violated Antitrust LawsRead the original story

    Jul 17, 2017 | Huntington News

    West Virginia Attorney General Patrick Morrisey joined a multistate lawsuit alleging antitrust violations involving an antibiotic, an oral diabetes medication and six generic drug manufacturers. The companies are accused of fixing prices, coordinating schemes through direct interactions with competitors and allocating markets among other assertions.

    Comment?

  3. West Virginia joins lawsuit alleging generic price fixingRead the original story w/Photo

    Jul 17, 2017 | The Intelligencer

    West Virginia's attorney general has joined three other states and the District of Columbia to sue six generic drugmakers, alleging they conspired to hike prices for a common antibiotic and a diabetes medication. Attorney General Patrick Morrisey says the allegations will be He joins attorneys general for Arkansas, Missouri, New Mexico and the District of Columbia in the suit filed Monday against Heritage Pharmaceuticals, Aurobindo Pharma USA, Citron Pharma, Mayne Pharma, Mylan Pharmaceuticals and Teva Pharmaceuticals.

    Comment?

  4. Attorney General Morrisey accuses drug manufacturers of price fixingRead the original story w/Photo

    Jul 17, 2017 | WOAY

    West Virginia Attorney General Patrick Morrisey joined a multistate lawsuit alleging antitrust violations involving an antibiotic, an oral diabetes medication and six generic drug manufacturers. The companies are accused of fixing prices, coordinating schemes through direct interactions with competitors and allocating markets among other assertions.

    Comment?

  5. Ex-N.J. pharma execs cooperate in probe into drug price hikesRead the original story w/Photo

    May 24, 2017 | The Jersey Journal

    TRENTON -- Two former executives at a Monmouth County company that manufactures generic pharmaceuticals agreed to cooperate in a multi-state investigation into whether multiple companies in the industry colluded to inflate drug prices, the state Attorney General's Office announced Wednesday. Jason Malek, the ex-president of Heritage Pharmaceuticals in Eatontown, and Jeffrey Glazer, the ex-chairman and chief executive officer of the company, have entered into settlement agreements with the states, saying they will cooperate in the anti-trust investigation by providing information, documents, testimony, depositions, and other evidence, authorities said.

    Comment?

  6. nateglinide, StarlixRead the original story w/Photo

    May 15, 2017 | MedicineNet

    Nateglinide is an oral drug used to lower blood sugar levels in type 2 diabetes . It is in a class of drugs called meglitinides which also includes repaglinide .

    Comment?

  7. I've seen over 8,000 medical professionals. Here's what I've learned.Read the original story w/Photo

    Apr 30, 2017 | Kevin, M.D.

    Today, I am a 40-year old with type 2 diabetes. I have been on glyburide since I was diagnosed four years ago and am otherwise healthy, although my blood pressure today is 140/96.

    Comment?

  8. Global Oral Antidiabetic Drugs Market to Exceed $35.91 Bn by 2022Read the original story w/Photo

    Apr 10, 2017 | SBWire

    Zion Market Research has published a new report titled " Oral Antidiabetic Drug Market by Drug Category for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022". According to the report, the global oral antidiabetic drug market accounted for USD 19.94 billion in 2016 and is expected to reach USD 35.91 billion by 2022, growing at a CAGR of around 10.2% between 2017 and 2022.

    Comment?

  9. Investigations Unfold Major Generic Drug Price-Inflation ConspiraciesRead the original story

    Mar 20, 2017 | Pharmacy Times

    The recent crackdown on generic drug price fixing has far-reaching implications, an investigation led by federal and state prosecutors has found. Mylan and Teva - 2 major generic industry players - and 4 smaller pharmaceutical companies are facing heat for wide-ranging drug price inflation conspiracies.

    Comment?

  10. Statins Warning: Cholesterol-lowering drug found to raise risk of...Read the original story w/Photo

    Mar 27, 2017 | NewsTarget.com

    Elderly women who take statins have an increased risk of developing type-2 diabetes , an Australian study found. Researchers at the University of Queensland examined more than 8,000 elderly female pensioners and found that those who took the cholesterol-lowering drug had a 33% increased risk of diabetes.

    Comment?

  11. ADA recommends metformin as the preferred drug treatment for type 2 diabetesRead the original story w/Photo

    Mar 13, 2017 | PhysOrg Weblog

    The American Diabetes Association recommends metformin as the first-line treatment for type 2 diabetes. Metformin monotherapy should be initiated at the time of diagnosis for most patients unless there are contraindications.

    Comment?

  12. Global Oral Antidiabetic Drugs Market Sales Is Growing at 10.2% CAGR Till 2022Read the original story w/Photo

    Mar 9, 2017 | SBWire

    Zion Market Research has published a new report titled " Oral Antidiabetic Drug Market by Drug Category for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022". According to the report, the global oral antidiabetic drug market accounted for USD 19.94 billion in 2016 and is expected to reach USD 35.91 billion by 2022, growing at a CAGR of around 10.2% between 2017 and 2022.

    Comment?

  13. Vermont joins 39 states in generic drug price lawsuitRead the original story

    Mar 7, 2017 | Washington Times

    Vermont has joined more than 30 other states in a national lawsuit that alleges a group of pharmaceutical companies conspired to fix the prices of generic drugs. State Attorney General T.J. Donovan says the lawsuit filed in federal court in Connecticut in December helps address the "harm caused by generic drug manufacturers who seek to maximize their profits at the expense of consumers."

    Comment?

  14. Perrigo Company PLC (PRGO) Becomes The Latest Pharma Investigated Over Price FixingRead the original story w/Photo

    Mar 6, 2017 | Insider Monkey

    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. We only allow registered users to use ad blockers.

    Comment?

  15. NH joins suit alleging collusion between drug makersRead the original story w/Photo

    Mar 5, 2017 | UnionLeader.com

    The school announced last year that history teacher Rick Schubart had previously admitted to student-involved sexual misconduct that took place in the 1970s and again in the 1980s.

    Comment?

  16. NH joins suit alleging collusion between drug makersRead the original story w/Photo

    Mar 1, 2017 | UnionLeader.com

    New Hampshire has joined in the lawsuit against six generic drug makers accused of bid-rigging on two specific drugs - doxycycline hyclate delayed release, known as DOXY DR, prescribed for a range of conditions, including severe acne and respiratory tract infections, and glyburide, prescribed for diabetes.

    Comment?

  17. Twenty More States Accuse Mylan, Teva and Others of Price CollusionRead the original story w/Photo

    Mar 1, 2017 | TheStreet.com

    Twenty more states have joined the lawsuit filed in 2016 against Teva Pharmaceuticals , Mylan and other generic firms, alleging that they colluded to push up prices of two drugs. This was announced by the Connecticut's attorney general, George Jepsen in a press release Wednesday.

    Comment?

  18. Schuette Sues Six Generic Drug Companies Accused of Illegally Driving ...Read the original story

    Mar 1, 2017 | State of Michigan

    LANSING Attorney General Bill Schuette today joined a multi-state antitrust lawsuit against six generic drug companies that manufacture doxycycline hyclate delayed release, an antibiotic, and glyburide, an oral diabetes medication. The suit was filed against Heritage Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., Citron Pharma, LLC, Mayne Pharma , Inc., Mylan Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. over allegations that the companies engaged in an illegal scheme to reduce competition and manipulate prices, causing purchasers to pay artificially high prices for needed medications.

    Comment?

  19. Twenty U.S. states join generic drug price-fixing lawsuitRead the original story w/Photo

    Mar 1, 2017 | Reuters

    California, Illinois and 18 more states have joined a lawsuit filed last year alleging that six companies, including Mylan NV and Teva Pharmaceutical Industries Ltd, conspired to push up prices of two generic drugs, the Connecticut attorney general's office said on Wednesday. Connecticut, which leads the group, and 19 other states filed the original lawsuit on Dec. 15. It added the additional states in filing an amended complaint which also added violations of state antitrust laws, the Connecticut attorney general's office said in a statement.

    Comment?

  20. Forty U.S. states now suing generic drug makers over alleged price-fixingRead the original story w/Photo

    Mar 1, 2017 | Seeking Alpha

    Reuters reports that 20 additional states, including California and Illinois, have joined the original 20 in a lawsuit against generic drug makers over alleged price-fixing of two drugs, an antibiotic called doxycycline hyclate and a diabetes med called glyburide. The lawsuit involves Mylan NV , Teva Pharmaceutical Industries and four smaller generics firms.

    Comment?